Novel oral anticoagulants are frequently used for the pharmacotherapy of thromboembolic
disorders but still have drawbacks and side effects. While numerous synthetic and …

Direct oral anticoagulants are an important and relatively new class of synthetic
anticoagulant drugs commonly used for the pharmacotherapy of thromboembolic disorders …

Activated blood coagulation factor X (FXa) plays a critical initiation step of the blood-
coagulation pathway and is considered a desirable target for anticoagulant drug …

Abstract Coagulation Factor Xa (FXa) is the crucial enzyme at the convergent point of the
intrinsic and extrinsic coagulation pathways. The inhibition of FXa is an effective approach …

Abstract Coagulation factor Xa (Factor Xa, FXa) is a particularly promising target for novel
anticoagulant therapy. The first oral factor Xa inhibitor has been approved in the EU and …

The human factor XIIa is a serine protease enzyme that is implicated in the pathological
thrombosis. This coagulation factor represents an interesting molecular target to design …

Human coagulation factor XIIa (FXIIa) is a trypsin‐like serine protease that is involved in
pathologic thrombosis. As a potential target for designing safe anticoagulants, FXIIa has …

Factor Xa is an interesting target for design of new anticoagulants as it is positioned at the
beginning of the coagulation common pathway. In this study, two different modelling …

Abstract Coagulation factor Xa (FXa), a serine endopeptidase is a common coagulation
factor activated as a result of the initiation of both intrinsic and extrinsic blood coagulation …

Stevioside, one of the natural sweeteners extracted from stevia leaves, and its derivatives
are considered to have numerous beneficial pharmacological properties, including the …